The calendar
Every upcoming readout, decision and trial completion we track, drawn from ClinicalTrials.gov. Only companies whose ticker we could verify against SEC's register appear here, because a wrong ticker is worse than a missing one.
Loading catalysts…
153 catalysts · 30 companies
| Ticker | Catalyst | Phase | Expected |
|---|---|---|---|
| SNY | Phase 2 primary completion: Long-term Safety and Efficacy Evaluation of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical StudySanofi · Asthma | P2 | 2026-09-29in 1 months |
| AZN | Phase 3 primary completion: A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung CancerAstraZeneca · Metastatic Non-small Cell Lung Cancer | P3 | 2026-09-30in 2 months |
| IBRX | Phase 2 primary completion: A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder CancerImmunityBio, Inc. · Non-muscle Invasive Bladder Cancer | P2 | 2026-09-30 |
| BMY | Phase 2 primary completion: A Study of BMS-986449 With and Without Nivolumab in Participants With Advanced Solid TumorsBristol-Myers Squibb · Advanced Solid Tumors | P2 | 2026-09-30in 2 months |
| AZN | Phase 3 primary completion: A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung CancerAstraZeneca · Non-Small Cell Lung Cancer | P3 | 2026-09-30in 2 months |
| AZN | Phase 3 primary completion: Durvalumab Plus Tremelimumab as First-line Treatment in Chinese Patients With uHCCAstraZeneca · Hepatocellular Carcinoma | P3 | 2026-09-30in 2 months |
| IVBXF | Phase 3 primary completion: Neoadjuvant and Adjuvant Therapy Studies of Sindilizumab in Resectable Lung CancerInnovent Biologics (Suzhou) Co. Ltd. · Non-Small Cell Lung Cancer | P3 | 2026-09-30in 2 months |
| TAK | Phase 2 primary completion: A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative ColitisTakeda · Ulcerative Colitis | P2 | 2026-09-30in 2 months |
| BIIB | Phase 3 primary completion: A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus ErythematosusBiogen · Lupus Erythematosus, Systemic | P3 | 2026-09-30in 2 months |
| ARWR | Phase 2 primary completion: Study of ARO-DIMERPA in Adult Participants With Mixed HyperlipidemiaArrowhead Pharmaceuticals · Hyperlipidemia; Mixed | P2 | 2026-09-30in 2 months |
| IVBXF | Phase 2 primary completion: Tolerance and Pharmacokinetic/Pharmacokinetic Study of IBI362 15mg in Patients With Moderate to Severe ObesityInnovent Biologics (Suzhou) Co. Ltd. · Obesity | P2 | 2026-09-30in 2 months |
| OGN | Phase 3 primary completion: Tapinarof for the Treatment of Plaque Psoriasis in Pediatric SubjectsOrganon and Co · Plaque Psoriasis | P3 | 2026-10-01in 2 months |
| ABOS | Phase 2 primary completion: A Study to Evaluate Efficacy and Safety of Intravenous Sabirnetug in Participants With Early Alzheimer's Disease (ALTITUDE-AD)Acumen Pharmaceuticals · Alzheimer Disease | P2 | 2026-10-01in 2 months |
| XENE | Phase 3 primary completion: A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures (X-TOLE3)Xenon Pharmaceuticals Inc. · Focal Onset Seizures | P3 | 2026-10-01in 2 months |
| IRON | Phase 2 primary completion: Study of DISC-0974-201 in Participants With IBD and AnemiaDisc Medicine, Inc · Inflammatory Bowel Disease (IBD), Anemia, Inflammatory Bowel Disease (IBD); Anemia | P2 | 2026-10-01in 2 months |
| COCP | Phase 2 primary completion: A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CDI-988 in Healthy Adults After Challenge With Snow Mountain VirusCocrystal Pharma, Inc. · Norovirus | P2 | 2026-10-01in 2 months |
| SLGL | Phase 3 primary completion: Efficacy and Safety of Patidegib Gel 2% for Preventing Basal Cell Carcinomas on the Face of Adults With Gorlin SyndromeSol-Gel Technologies, Ltd. · Gorlin Syndrome | P3 | 2026-10-01in 2 months |
| MIRM | Phase 3 primary completion: Evaluation of Maralixibat in Pruritus Associated With General Cholestatic Liver Disease (EXPAND)Mirum Pharmaceuticals, Inc. · Cholestatic Liver Disease (Except ALGS, PFIC, PBC and PSC) | P3 | 2026-10-01in 2 months |
| NVO | Phase 3 primary completion: A Research Study Looking Into How Ziltivekimab Works Compared to Placebo in Participants With Heart Failure and InflammationNovo Nordisk A/S · Heart Failure, Systemic Inflammation | P3 | 2026-10-01in 2 months |
| IBRX | Phase 2 primary completion: A Study to Assess Anktiva in Patients With Long Covid-19.ImmunityBio, Inc. · Long COVID | P2 | 2026-10-01in 2 months |
| VNDA | Phase 2 primary completion: Evaluation of Efficacy and Safety of Iloperidone for the Treatment of Participants With Uncontrolled HypertensionVanda Pharmaceuticals · Hypertension, Uncontrolled Hypertension | P2 | 2026-10-01in 2 months |
| PHAT | Phase 2 primary completion: A Study in Adult Participants With EoE to Evaluate Vonoprazan 20 mg Compared to Placebo After 12 Weeks and to Evaluate Vonoprazan 20 mg Up to 24 WeeksPhathom Pharmaceuticals, Inc. · Eosinophilic Esophagitis | P2 | 2026-10-01in 2 months |
| GILD | Phase 2 primary completion: Study of Sacituzumab Govitecan in Patients With Solid TumorGilead Sciences · Solid Tumor | P2 | 2026-10-01in 2 months |
| CLDX | Phase 3 primary completion: A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous UrticariaCelldex Therapeutics · Chronic Spontaneous Urticaria | P3 | 2026-10-01in 2 months |
| LLY | Phase 3 primary completion: A Study of Baricitinib (LY3009104) in Participants From 1 Year to Less Than 18 Years Old With Systemic Juvenile Idiopathic Arthritis (sJIA)Eli Lilly and Company · Systemic Juvenile Idiopathic Arthritis | P3 | 2026-10-01in 2 months |
| CRNX | Phase 2 primary completion: A Study to Evaluate the Safety and PK of CRN04894 for the Treatment of Cushing's SyndromeCrinetics Pharmaceuticals Inc. · Cushing Syndrome, Cushing Disease, Ectopic ACTH Syndrome | P2 | 2026-10-01in 2 months |
| CLDX | Phase 3 primary completion: A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria (CSU)Celldex Therapeutics · Chronic Spontaneous Urticaria | P3 | 2026-10-01in 2 months |
| ABBV | Phase 3 primary completion: Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMDAbbVie · AMD, nAMD, Wet Age-related Macular Degeneration, wAMD, WetAMD, CNV | P3 | 2026-10-01in 2 months |
| CORT | Phase 2 primary completion: Dazucorilant in Patients With Amyotrophic Lateral SclerosisCorcept Therapeutics · Amyotrophic Lateral Sclerosis | P2 | 2026-10-01in 2 months |
| TAK | Phase 3 primary completion: A Trial of TAK-861 for the Treatment of Narcolepsy With CataplexyTakeda · Narcolepsy Type 1 (NT1), Narcolepsy With Cataplexy | P3 | 2026-10-02in 2 months |
| BMY | Phase 3 primary completion: A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary FibrosisBristol-Myers Squibb · Idiopathic Pulmonary Fibrosis | P3 | 2026-10-06in 2 months |
| REGN | Phase 3 primary completion: Study to Assess the Long-term Safety of Dupilumab Administered in Participants ≥6 Months to <18 Years of Age With Atopic Dermatitis (AD)Regeneron Pharmaceuticals · Atopic Dermatitis | P3 | 2026-10-07in 2 months |
| REGN | Phase 3 primary completion: A Study to Evaluate How Safe Pozelimab + Cemdisiran Combination Therapy is and How Well it Works in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Have Not Recently Received or Have Not Received Complement Inhibitor TreatmentRegeneron Pharmaceuticals · Paroxysmal Nocturnal Hemoglobinuria | P3 | 2026-10-12in 2 months |
| BMY | Phase 2 primary completion: A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple MyelomaBristol-Myers Squibb · Multiple Myeloma | P2 | 2026-10-12in 2 months |
| SNY | Phase 3 primary completion: A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal PolypsSanofi · Chronic Rhinosinusitis With Nasal Polyps | P3 | 2026-10-14in 2 months |
| AZN | Phase 2 primary completion: A Study to Characterize the Safety and Immunogenicity of AZD6489 in Participants 60 Years of Age and Older (ARIES)AstraZeneca · RSV Respiratory Syncytial Virus | P2 | 2026-10-15in 2 months |
| SLDB | Phase 2 primary completion: Microdystrophin Gene Transfer Study in Adolescents and Children With DMDSolid Biosciences Inc. · Duchenne Muscular Dystrophy | P2 | 2026-10-15in 2 months |
| PFE | Phase 2 primary completion: A Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In People Who Have Moderate To Severe Atopic DermatitisPfizer · Atopic Dermatitis | P2 | 2026-10-19in 2 months |
| BMY | Phase 3 primary completion: A Study to Evaluate Effectiveness and Safety of Deucravacitinib (BMS-986165) Compared With Placebo in Participants With Active Systemic Lupus ErythematosusBristol-Myers Squibb · Systemic Lupus Erythematosus | P3 | 2026-10-19in 2 months |
| BMY | Phase 3 primary completion: A Study to Assess Effectiveness and Safety of Deucravacitinib Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE)Bristol-Myers Squibb · Systemic Lupus Erythematosus | P3 | 2026-10-19in 2 months |
| BIIB | Phase 3 primary completion: A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus ErythematosusBiogen · Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythematosus | P3 | 2026-10-20in 2 months |
| AMGN | Phase 3 primary completion: A Safety and Efficacy Study of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-Severe Symptom StateAmgen · Sjögren's Syndrome (SS) | P3 | 2026-10-22in 2 months |
| AZN | Phase 2 primary completion: Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary CancerAstraZeneca · Hepatocellular Carcinoma, Biliary Tract Cancer | P2 | 2026-10-27in 2 months |
| VRTX | Phase 3 primary completion: A Study Evaluating the Long-term Safety and Efficacy of VX-121 Combination TherapyVertex Pharmaceuticals Incorporated · Cystic Fibrosis | P3 | 2026-10-30in 3 months |
| AMGN | Phase 2 primary completion: A Phase 2 Study of Anvumetostat in Participants With MTAP-deleted Advanced NSCLC (MTAPESTRY 201)Amgen · MTAP-deleted NSCLC | P2 | 2026-10-31in 3 months |
| ANNX | Phase 3 primary completion: A Study Investigating the Efficacy and Safety of Intravitreal (IVT) Injections of Vonaprument (Formerly ANX007) in Participants With Dry Age-Related Macular Degeneration (AMD) With Geographic Atrophy (GA)Annexon, Inc. · Geographic Atrophy | P3 | 2026-10-31in 3 months |
| AZN | Phase 3 primary completion: Capivasertib+Fulvestrant asTreatment for Locally Advanced(Inoperable) or Metastatic HR+/HER2- Breast Cancer in Chinese PatientsAstraZeneca · Breast Cancer | P3 | 2026-10-31in 3 months |